Another spike MAB.. if they were the answer, why h
Post# of 148188
Quote:
patients treated early with VIR-7831 monotherapy compared to placebo.
A bigger factor:
Quote:
On March 3, 2021, the companies were informed that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses were available data raised concerns about the magnitude of potential benefit. The independent Data and Safety Monitoring Board (DSMB) has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. George Scangos stated in a related press release, “While we are disappointed with the recommendation of the DSMB, we are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients."
http://www.pmlive.com/pharma_news/gsk,_vir_ha...IGN_NAME=2